TH1/TH2 细胞因子模式可预测醋酸格拉替雷治疗多发性硬化症患者的临床反应。
Patterns of TH1/TH2 cytokines predict clinical response in multiple sclerosis patients treated with glatiramer acetate.
机构信息
Department of Neurology, University of Ulm, Oberer Eselsberg 45, Ulm, Germany.
出版信息
Eur Neurol. 2011;65(3):164-9. doi: 10.1159/000324035. Epub 2011 Mar 3.
The patterns of Th1/Th2 cytokines in relapsing-remitting multiple sclerosis were analyzed to evaluate their relevance as biomarkers of therapy response to glatiramer acetate (GA). Serum interferon-γ (IFN-γ), osteopontin and interleukin (IL)-2, IL-4, and IL-10 were measured in 19 relapsing-remitting multiple sclerosis patients treated with GA in a prospective study over 3 years. The quotient (IL-2 + IFN-γ)/(IL-4 + IL-10) was elevated in patients with relapses as compared to relapse-free patients after 12 (p = 0.04), 24 (p = 0.02) and 36 months (p = 0.04). Our study indicates that specific patterns of Th1/Th2 cytokines predict the response to GA therapy.
分析复发缓解型多发性硬化症患者的 Th1/Th2 细胞因子模式，以评估其作为对醋酸格拉替雷治疗反应的生物标志物的相关性。在一项为期 3 年的前瞻性研究中，对 19 例接受 GA 治疗的复发缓解型多发性硬化症患者进行了血清干扰素-γ (IFN-γ)、骨桥蛋白和白细胞介素 (IL)-2、IL-4 和 IL-10 的测定。与缓解后无复发的患者相比，复发患者的 IL-2 + IFN-γ)/(IL-4 + IL-10) 比值在 12 (p = 0.04)、24 (p = 0.02) 和 36 个月 (p = 0.04) 时升高。我们的研究表明，Th1/Th2 细胞因子的特定模式可预测对 GA 治疗的反应。
Zotero 插件